Inhibition of EZH2 Catalytic Activity Selectively Targets a Metastatic Subpopulation in Triple-Negative Breast Cancer
Shira Yomtoubian, Sharrell B. Lee, Akanksha Verma, Franco Izzo, Geoffrey J. Markowitz, Hyejin Choi, Leandro Cerchietti, Linda T. Vahdat, Kristy A. Brown, Eleni Andreopoulou, Olivier Elemento, Jenny C. Chang, Giorgio Inghirami, Dingcheng Gao, Seongho Ryu, Vivek Mittal
Abstract
luminal androgen receptor subtype. These preclinical findings provide a rationale for clinical development of EZH2 as a targeted therapy against TNBC metastasis.
Topics & Concepts
EZH2Cancer researchBreast cancerEpigeneticsTriple-negative breast cancerPopulationBiologyMetastasisCancerMedicineGeneticsGeneEnvironmental healthEpigenetics and DNA MethylationCancer Genomics and DiagnosticsRNA modifications and cancer